BR100 Increased By (0.8%)
BR30 Increased By (0.86%)
KSE100 Increased By (0.8%)
KSE30 Increased By (0.87%)
AGHA 6.37 Decreased By ▼ -0.01 (-0.16%)
BECO 4.37 Increased By ▲ 0.02 (0.46%)
BML 62.70 Increased By ▲ 0.15 (0.24%)
BOP 31.38 Decreased By ▼ -0.01 (-0.03%)
CNERGY 11.77 Increased By ▲ 0.04 (0.34%)
CSIL 5.75 Decreased By ▼ -0.16 (-2.71%)
FCCL 61.65 Decreased By ▼ -0.06 (-0.1%)
FFL 14.89 Increased By ▲ 0.10 (0.68%)
FNEL 1.28 Increased By ▲ 0.04 (3.23%)
KEL 6.33 Increased By ▲ 0.01 (0.16%)
KOSM 5.80 Decreased By ▼ -0.10 (-1.69%)
LOTCHEM 24.83 Increased By ▲ 0.14 (0.57%)
MLCF 105.65 Increased By ▲ 1.72 (1.65%)
NBP 174.43 Increased By ▲ 1.11 (0.64%)
NCPL 52.50 Increased By ▲ 0.67 (1.29%)
NPL 54.95 Increased By ▲ 0.92 (1.7%)
OGDC 318.35 Increased By ▲ 2.48 (0.79%)
PACE 9.25 Decreased By ▼ -0.01 (-0.11%)
PAEL 35.90 Increased By ▲ 0.32 (0.9%)
PIBTL 14.14 Increased By ▲ 0.48 (3.51%)
PPL 229.20 Increased By ▲ 3.13 (1.38%)
PRL 81.30 Increased By ▲ 1.02 (1.27%)
PTC 47.00 Increased By ▲ 0.36 (0.77%)
SSGC 23.97 Increased By ▲ 0.15 (0.63%)
TBL 9.34 Increased By ▲ 0.10 (1.08%)
TELE 7.63 Increased By ▲ 0.08 (1.06%)
TPL 24.82 Increased By ▲ 0.28 (1.14%)
TPLP 12.97 Decreased By ▼ -0.02 (-0.15%)
TREET 27.07 Increased By ▲ 1.09 (4.2%)
TRG 53.92 Increased By ▲ 0.59 (1.11%)
By

BENGALURU: Johnson & Johnson said it will discontinue the late-stage study of its experimental respiratory syncytial virus (RSV) adult vaccine, weeks after rivals Pfizer and GSK gained a lead in the race for the first vaccine against the virus.

J&J made the decision in order to “to focus on medicines with the greatest potential benefit to patients,” the company said on Wednesday.

The drugmaker, which started the global study in September 2021 in about 23,000 adults aged 60 years and older, did not provide any further details about the trial.

J&J started the study following positive results from a mid-stage trial, which showed the vaccine was 80% effective in protecting against lower respiratory tract disease caused by RSV.

Pfizer and GSK’s RSV vaccines gained the backing of a panel of US Food and Drug Administration advisers in late February and early March, bringing them a step closer to approval in the United States. The health regulator is expected to decide on the two vaccines by May.

Pfizer and GSK are running a tight race to tap into the RSV vaccine market, which is estimated to be more than $5 billion and could exceed $10 billion by 2030, according to analysts.

There is currently no approved vaccine to prevent lower respiratory tract disease caused by RSV in older adults.

Comments

Comments are closed for this article.